Cyclizine

Cyclizine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Cyclizine is an antihistamine that is FDA approved for the treatment of and prevention of nausea, vomiting, or dizziness associated with motion sickness. For the treatment of vertigo of motion sickness. Common adverse reactions include drowsiness.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

• Adults and children 12 years of age and over: 2 tablets every 4-6 hours, not to exceed 8 tablets in 24 hours.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cyclizine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cyclizine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

• Adults and children 12 years of age and over: 2 tablets every 4-6 hours, not to exceed 8 tablets in 24 hours.
• Children 6 to under 12 years of age: 1 tablet every 6-8 hours, not to exceed 3 tablets in 24 hours.
• Children under 6 years of age: Consult a physician.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cyclizine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cyclizine in pediatric patients.

Contraindications

There is limited information regarding Cyclizine Contraindications in the drug label.

Warnings

• Do not exceed recommended dosage.
• Ask a doctor or pharmacist before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland
• Ask a doctor before use if you are taking sedatives, or tranquilizers.
• Do not give this product to children who have a breathing problem such as chronic bronchitis or who have glaucoma, without first consulting the child's doctor.
• Do not give to children under 6 years of age unless directed by a doctor.
• When using this product you may get drowsy avoid alcohol drinks alcohol, sedatives, and tranquilizers may increase the drowsiness effect be careful when driving a motor vehicle or operating machinery
• In case of overdose, get medical help or contact a Poison Control Center right away.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Cyclizine Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Cyclizine Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Cyclizine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): If pregnant or breast-feeding, ask a health professional before use.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Cyclizine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Cyclizine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Cyclizine in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Cyclizine in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Cyclizine in geriatric settings.

Gender

There is no FDA guidance on the use of Cyclizine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Cyclizine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Cyclizine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Cyclizine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Cyclizine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Cyclizine in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Cyclizine Administration in the drug label.

Monitoring

There is limited information regarding Cyclizine Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Cyclizine and IV administrations.

Overdosage

There is limited information regarding Cyclizine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Mechanism of Action

There is limited information regarding Cyclizine Mechanism of Action in the drug label.

Structure

Pharmacodynamics

There is limited information regarding Cyclizine Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Cyclizine Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Cyclizine Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Cyclizine Clinical Studies in the drug label.

How Supplied

There is limited information regarding Cyclizine How Supplied in the drug label.

Storage

There is limited information regarding Cyclizine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Cyclizine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Cyclizine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Cyclizine Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Cyclizine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

• Marezine
• Bonine for Kids
• Cyclivert

Look-Alike Drug Names

There is limited information regarding Cyclizine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Label Page=Cyclizine
 |Label Name=CyclizinePack1.png

}}

{{#subobject:

 |Label Page=Cyclizine
 |Label Name=CyclizinePack2.png

}}

{{#subobject:

 |Label Page=Cyclizine
 |Label Name=CyclizinePack3.png

}}

Cyclizine

File:Cyclizine.svg
Clinical data
Pregnancy category	A (Au)
Routes of administration	Oral, IM, IV
ATC code	R06AE03 (WHO)
Legal status
Legal status	P/POM (UK)
Pharmacokinetic data
Metabolism	N-demethylated to inactive norcyclizine
Elimination half-life	20 hours
Identifiers
IUPAC name 1-benzhydryl-4-methyl-piperazine
CAS Number	82-92-8
PubChem CID	6726
DrugBank	APRD00061
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H22N2
Molar mass	266.381 g/mol
3D model (JSmol)	Interactive image
SMILES CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3